Abstract library

235 results for "extrahepatic evaluation".
#2113 How to Perform Contrast Enhanced Oncologic Staging MRI of Abdomen and Pelvis with a Hepatocyte Specific Agent in a Large Bore MR Scanner: Optimizing Extrahepatic Tumor Evaluation in Neuroendocrine Neoplasms
Introduction: Liver specific MR contrast agents in neuroendocrine neoplasms (NEN) have shown its advantages in evaluation of hepatic tumor burden. However, a standard scan protocol is insufficient in extrahepatic and especially pelvic tumor evaluation.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr. Uli Fehrenbach
#1805 Application of Parametric Contrast-Enhanced Ultrasound for Early Treatment Response Evaluation in Metastatic Hepatic Neuroendocrine Neoplasm
Introduction: Since shrinkage of lesions in patients with metastatic hepatic neuroendocrine neoplasm (MHNEN) receiving systemic therapy is rarely observed,limit of RECIST for evaluating treatment response gradually emerged.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: house physician Xiaona Lin
Authors: Lin X, Chen J, Xu M, Xie X, ...
#1359 Multicenter Retrospective Analysis of Clinical and Pathological Features of Gallbladder and Extrahepatic Biliary Duct Neuroendocrine Neoplasm
Introduction: Primary neuroendocrine neoplasm of the gallbladder(GB) and extrahepatic biliary duct(EHBD) were considered as rare malignant tumors.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Panpan Zhang
Authors: Zhang P, Lu M, Chen J, Chen Y, ...
#1644 Pitfalls in the Response Evaluation after Peptide Receptor Radionuclide Therapy with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: PPRT with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic GEPNETs
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Tessa Brabander
#299 Clinical and Immunohistochemical Evaluation of Medullary Thyroid Cancer (MTC) and C Cell Hyperplasia (CCH)
Introduction: MTC and CCH has a variable clinical presentation and prognosis and no data are available on the correlation between immunoistochemical (IIC) characterization and clinical behavior.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Prof Laura De Marinis
Authors: Lugli F, Fusco A, Bianchi A, Milardi D, ...
#1157 Cardiac Evaluation as Part of the Initial Extension Studies in Neuroendocrine Tumors. Experience in a Multidisciplinary Team. ARGENTUM GROUP
Introduction: Carcinoid heart disease (CHD) is a complication of metastatic neuroendocrine tumors and is screened for using echocardiography. Published case series showed that when cardiological evaluation is done at least 50% of the patients have CHD, and 33% had surgical indication.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Juan Manuel O'Connor
#987 Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional MRI in Pancreatic Neuroendocrine Tumors and Comparison with 68Ga-DOTANOC PET/CT
Introduction: Pancreatic neuroendocrine tumors (pNETs) are often difficult to detect because of small size and have variable prognosis related to grading and staging.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Maria Gabriella Brizi
#1155 Evaluation of Features and Predictors for Long Term Hematologic Toxicity in Neuroendocrine Patients Treated with Peptide Receptor Radionuclide Therapy
Introduction: Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET) may offer partial or complete objective response in up to 30% of patients. To deliver treatment in a safe and effective manner, long term adverse events should be considered.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Suzanne Richter
Keywords: PRRT
#613 Preclinical Evaluation of Novel Combinations of 177-Lutetium Octreotate with Molecular Targeted Agents in Neuroendocrine Tumor Models
Introduction: Peptide receptor radionuclide therapy (PRRT) has been valuable in the treatment of somatostatin receptor-2 (SSTR2) expressing neuroendocrine tumors (NET) but more effective clinical regimens are needed.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Carleen Cullinane
Authors: Cullinane C, Waldeck K, Kirby L, Eu P, ...
#667 Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors after Treatment with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: Response Evaluation Criteria in Solid Tumors (RECIST) (unidimensional), Southwest Oncology Group (SWOG) solid tumor response criteria (bidimensional), and their modified variants (mRECIST/mSWOG) are used to assess treatment response in gastroenteropancreatic and thoracic neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Esther I Van Vliet